


|   |            |                         |
|---|------------|-------------------------|
| <b>Patient:</b>   | Client:    | ARUP Test Code: 3000146 |
| DOB:                      Age:                      Gender: | Physician: | Collection Date:        |
| <b>Patient Identifiers:</b>                                 |            | Received in lab:        |
| Visit Number (FIN):   |            | Completion Date:        |

**Interpretation: SCREEN POSITIVE**  
**Follow-up for risk of Downs and Trisomy 18 is suggested**


**Down syndrome (DS): Positive**

Risk before test: **1 in 114**  
 Risk after test: **1 in 22**



**Trisomy 18 (T18): Positive**

Risk before test: **1 in 2380**  
 Risk after test: **1 in 2**



**Comments:**

| Marker | Measurement | MoM  |
|--------|-------------|------|
| PAPP-A | 80.0 ng/mL  | 0.11 |
| hCG    | 14524 IU/L  | 0.17 |
| NT     | 2.50 mm     | 2.03 |



Patient: ARUP Accession: 21-118-155231

# Maternal Screening, Sequential, Specimen #1, hCG, PAPP-A, NT

Patient: | Date of Birth: | Gender: | Physician:  
Patient Identifiers: | Visit Number (FIN):

The risk of Down syndrome is greater than the screening cut-off. Other outcomes of positive screens include normal pregnancy, over-estimated gestational age, and fetal demise. Genetic counseling regarding the risks and benefits of cell-free DNA (NIPT) and fetal diagnostic testing is suggested. If you have questions regarding this screen, please call Genetics at 800-242-2787 ext 2141.

The risk of trisomy 18 is greater than the screening cut-off. Other outcomes of positive screens include normal pregnancy, increased risk for miscarriage, fetal demise, low birth weight and preterm labor, nonchromosomal anomalies and genetic syndromes. Genetic counseling regarding the risks and benefits of cell-free DNA (NIPT) and fetal diagnostic testing is suggested. If you have questions regarding this screen, please call Genetics at 800-242-2787 ext 2141.

The information submitted indicates that the patient had a previous pregnancy with a trisomy. This increases the pre-test risk of Down syndrome and Trisomy 18 in this pregnancy.

Information provided indicates that the patient was exposed to carbamazepine during this pregnancy. Infants who have been exposed to antiepileptic drugs (AEDs) in utero run an increased risk of congenital malformations, including neural tube defects (NTDs). Use of polytherapy with more than one AED appears to be associated with a higher risk of birth defects compared with monotherapy. Based on this information, the risk of neural tube defect is increased 9 times. Genetic counseling is recommended.

PAPP-A Maternal Compliance Statement: This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Maternal Screen Interpretation Compliance Statement: This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

## Patient Information Used in Risk Calculations:

Maternal Age at Delivery: 31.2 yr  
Maternal Weight: 206.0 lbs.  
Gestational Age at Draw: 11 wks, 6 days



Patient: ARUP Accession: 21-118-155231

# Maternal Screening, Sequential, Specimen #1, hCG, PAPP-A, NT

Patient: | Date of Birth: | Gender: | Physician:  
Patient Identifiers: | Visit Number (FIN):

Number of Fetuses: Singleton  
Maternal Race: Black  
Current Smoker: No  
Family History of Aneuploidy: Yes  
Specimen: Initial sample  
Crown Rump Length: 53.3 mm  
Sonographer Certification #:  
Sonographer Name:  
Ultrasound Date: 04-28-21  
Best Date to Draw Sample #2 By: 06-10-21

## Reference Information

The following links or information offer complete and up to date information about this test, including access to ARUP Consult™ disease topics and other supplemental resources.

- [Maternal Screening, Sequential, Specimen #1, hCG, PAPP-A, NT](http://ltd.aruplab.com/tests/pub/3000146)  
(http://ltd.aruplab.com/tests/pub/3000146)
- [Prenatal Aneuploidy Screening](https://www.aruplab.com/genetics/tests/prenatal)  
(https://www.aruplab.com/genetics/tests/prenatal)
- [Additional Technical Information](http://ltd.aruplab.com/Tests/Pdf/311)  
(http://ltd.aruplab.com/Tests/Pdf/311)



Patient:

ARUP Accession: 21-118-155231